FDA drops black‑box warnings from three menopause patches without advisory panel

The US Food and Drug Administration announced on Friday that black‑box warnings will be removed from three estrogen patches used to treat menopause, according to the Guardian. Officials said the agency did not convene an advisory committee and provided few details on the scientific basis for the decision during a press briefing.

The Guardian reported that some experts expressed concern about ‘lack of transparency’ as the agency moves forward with the change. The latest action follows a February decision that stripped black‑box warnings from six other menopause treatments.

Patients across the United States are currently facing shortages of these patches, a situation that has heightened scrutiny of the FDA’s regulatory approach.

Why it matters

Removing the strongest safety warnings could alter how doctors and patients assess risks, especially while supply shortages limit access to treatment.

Key details

Location

United States · Americas

Reported by

The Guardian

First reported

30 Oct 2026, 21:45 IST

Key names

FDA, US Food, Drug Administration

Section

Health

Sources

This is an independent summary. Read the full, original reporting from the publisher:

• The GuardianFDA again bypasses advisers to remove black-box warnings from menopause treatments 30 Oct, 21:45

Read the full story at The Guardian ↗

Spotted an error? Request a correction · How this summary was produced